LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

MannKind Corp

Open

SectorHealthcare

5.42 2.07

Overview

Share price change

24h

Current

Min

5.27

Max

5.44

Key metrics

By Trading Economics

Income

-12M

668K

Sales

-1.8M

77M

P/E

Sector Avg

48.909

35.664

Profit margin

0.873

Employees

403

EBITDA

-17M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+91.26% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

518M

1.7B

Previous open

3.35

Previous close

5.42

News Sentiment

By Acuity

50%

50%

185 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 wrz 2025, 17:03 UTC

Major Market Movers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 wrz 2025, 16:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 wrz 2025, 16:11 UTC

Major Market Movers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 wrz 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 wrz 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 wrz 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 wrz 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 wrz 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 wrz 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 wrz 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 20:25 UTC

Earnings

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 wrz 2025, 20:24 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 wrz 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 wrz 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 wrz 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 wrz 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 wrz 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 wrz 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 wrz 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 wrz 2025, 16:53 UTC

Earnings

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 wrz 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 16:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 wrz 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 wrz 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

91.26% upside

12 Months Forecast

Average 10.29 USD  91.26%

High 15 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

185 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat